AHPA recommends CBD not be scheduled under any international drug control convention

Market Alerts

July 2022

June 2022

May 2022

April 2022

February 2022

November 2021

  • SCNM Dedicates Ric Scalzo Institute of Botanical Research
  • August 2021

    July 2021

    March 2021

    February 2021

    November 2020

    October 2020

    September 2020

    August 2020

    July 2020

    June 2020

    April 2020

    February 2020

    January 2020

  • Sabinsa's parent company Sami Labs breaks ground on $30 million state of the art production facility
  • Unstoppable Moms Across America launches new Gold Standard to shift the marketplace for a healthier planet
  • Draco Achieves Safe Quality Food (SQF) certification of its manufacturing facilities
  • August 2019

    June 2019

    May 2019

    March 2019

    February 2019

    January 2019

    December 2018

    November 2018

    October 2018

    September 2018

    August 2018

    July 2018

    May 2018

    April 2018

    March 2018

    February 2018

    January 2018

    December 2017

    November 2017

    October 2017

    September 2017

    August 2017

    July 2017

    June 2017

    AHPA recommends CBD not be scheduled under any international drug control convention

    April 24, 2018: AHPA submits comments to FDA to inform participation in WHO Expert Committee on Drug Dependence

    Published: Tuesday, April 24, 2018

    AHPA submitted comments to the Food and Drug Administration (FDA) yesterday to stress that cannabidiol (CBD) requires no international drug scheduling as an individual substance and encourage the U.S. to support this position.

    AHPA's comments were in response to an April 9 FDA request for input concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of five cannabis derived drug substances, including CBD. The input gathered by FDA will be considered in preparing the U.S. response at the World Health Organization's (WHO's) 40th Expert Committee on Drug Dependence (ECDD) being held in Geneva, Switzerland on June 4-8.

    AHPA's comments express support for the November 2017 conclusions of the WHO 39th ECDD which state that CBD is not currently a scheduled substance on its own (only as a component of cannabis extracts) and that current information does not justify a change in this scheduling status nor does it justify scheduling of the substance.

    "Given that ECDD found no case reports of abuse or dependence relating to the use of CBD, extracts or preparations containing almost exclusively CBD should be subject to critical review at the upcoming meeting," said AHPA President Michael McGuffin. "AHPA is not aware of any information that suggests that extracts or preparations of Cannabis containing almost exclusively CBD are any more subject to abuse or dependence than CBD itself and therefore recommends and requests that the U.S. support a position to acknowledge that these extracts and preparations should not be scheduled under any international drug control convention."

    View and download AHPA's comments >>

    Print

    2022 Annual Fund Sponsors

    AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.